Pharmaceutical

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

Investment comes at a pivotal moment for Alpha Tau, which is experiencing remarkable growth on multiple fronts, with four active…

8 months ago

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

New Data Suggest SLS009 (tambiciclib) May Overcome Resistance to Azacitidine-Venetoclax Regimen and Trigger Apoptosis of TP53 Mutated AML CellsNEW YORK,…

8 months ago

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12’s Effectiveness in Treating Psoriasis

ART26.12 Phase 1 in healthy volunteers completes enrollment with clinical data announcement expected this quarterSOLANA BEACH, Calif., April 28, 2025 (GLOBE…

8 months ago

Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025

SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on…

8 months ago

2025 (Spring) Pharmaceutical Machinery Exposition Concludes Successfully

BEIJING, April 27, 2025 (GLOBE NEWSWIRE) -- On April 25, 2025, the 66th (Spring 2025) National Pharmaceutical Machinery Exposition &…

8 months ago

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf…

8 months ago

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patientsTARA-002 demonstrates…

8 months ago

GenVivo Highlights GEN-1013: A Novel Delivery of an IL-12 Immunotherapy at the 2025 American Association for Cancer Research (AACR) Annual Meeting

GEN-1013 was studied in an aggressive CT26 murine cancer model using both IT and IV administration.Significant tumor reduction was observed…

8 months ago

Burnjaro Under Review: Analyzing the Results of Burn Jaro Slimming Ingredients to Instantly Burn Belly Fat

Burnjaro Burnjaro Norcross, Georgia, April 26, 2025 (GLOBE NEWSWIRE) -- In This Article, You’ll Discover: Why belly fat is harder…

8 months ago